Two years ago, psychedelic medicine was getting written off. Lykos got rejected, funding dried up, and the conventional expert consensus was that the field had gotten ahead of its evidence. On July 16, Eli Lilly agreed to pay $2.8 billion upfront (up to $3.8 billion with milestones) for AtaiBeckley, whose lead asset is an intranasal form of 5-MeO-DMT now in Phase 3 for treatment-resistant depression, with Breakthrough Therapy designation from the FDA. AbbVie already did its own psychedelics deal with Gilgamesh. J&J's Spravato is running at a $2.5 billion annual rate. The largest pharmaceutical companies in the world have decided this modality is real, and they are buying up the pipelines to prove it.
Beyond the money, it is how they are talking about this modality that matters. Lilly described the pipeline as neuroplastogens: compounds designed to restore synaptic plasticity rather than modulate neurotransmitter levels. A trillion-dollar pharma company now frames depression as a loss of the brain's capacity to form and strengthen connections, and treatment as the work of restoring it.
This is the exact framework root-cause medicine has championed for years. Addressing depression means repairing the terrain by modulating inflammation, correcting sleep architecture, and optimizing the gut-brain axis, rather than simply boosting a signal. What the medical establishment once dismissed as fringe is now the driving thesis of Big Pharma's next decade of development.
The delivery model is the other tell
BPL-003 arrives as an in-office, monitored dosing session. It is short by design, with patients dischargeable in about two hours, following the interventional paradigm Spravato established, and it remains a supervised clinical visit rather than a script sent to CVS. Nothing about that fits a seven-minute insurance encounter. It fits a practice built on longer appointments, high-touch follow-up, and protocols that unfold over months. Interventional psychiatry's delivery model looks far more like our practices than like the system most of these patients are currently stuck in. The practices structurally ready for this class of medicine are the ones already built for time and depth.
What this means for the toolkit today
Nothing changed prescriptively this month. BPL-003 just entered Phase 3, and readouts are not expected until around 2029. The list of psychedelics available in practice today is short: ketamine (generic, off-label) and esketamine (Spravato, FDA-approved for TRD under a REMS program, including as a standalone monotherapy since early 2025). Everything else is investigational: 5-MeO-DMT, psilocybin, and the MDMA-adjacent compounds.
What did change is the conversation
Our patients are exactly the population that reads this news. They are the ones already asking about psilocybin retreats and microdosing. A $2.8 billion Lilly deal moves those questions from the margins of a visit to the middle of it. So what does the near-term work look like? Preparedness. Know the regulatory status of each compound, know the local referral pathways for ketamine-assisted therapy and clinical trials, and have a clear answer for the patient who asks whether she should wait for "the Lilly drug."
For a longevity practice, this does not belong filed under psychiatry. Depression accelerates biological aging and degrades adherence to everything else in the plan: the sleep protocol, the training block, the metabolic work. A practice that cannot engage seriously with mental health has a gap in its stack, and Lilly just marked that gap as where the next decade of neuroscience money is going.
The compounds are years away. The patients asking about them are in our exam rooms now.
What to try this week
Write your answer to the question you are about to get. Some version of "should I wait for the Lilly drug?" is coming. Draft two sentences now so you are not improvising. Something like: "That compound is at least three years from approval, and we don't know yet who it will help. If depression is affecting you now, we have options now. Let's not outsource this to a press release." Adjust it to your own voice, but have it ready.
Map your referral landscape in 30 minutes. Identify the Spravato-certified providers and reputable ketamine-assisted therapy practices within reach of your patients, and note which ones you would actually send someone to. Then search ClinicalTrials.gov for recruiting psychedelic trials in your region (try "psilocybin," "5-MeO-DMT," and "treatment-resistant depression"). Keep the list where your staff can find it.
Find the TRD patients already in your panel. Treatment-resistant depression means inadequate response to two or more adequate antidepressant trials. Run through your active patients, or query the EHR if it can do this, and flag who meets that bar. These are the people this news is about, and the ones who should hear it from you before they read it somewhere else.
Add one screening question to your intake. "Have you used or considered ketamine, psilocybin, or other psychedelic therapies?" Patients are already doing this through retreats, microdosing, and gray-market sources, and most will not volunteer it. You cannot manage interactions or set expectations around something you do not know about.
If you run a longevity practice, put mood on the dashboard. If you are trending ApoB and VO2 max without tracking a PHQ-9 or GAD-7 at the same cadence, this is the week to add it. You cannot claim to extend healthspan while flying blind on the variable that degrades adherence to everything else.
Be a modern clinician with the help of Ultralight, the AI-native EHR built specifically for functional, integrative, and longevity medicine. We’ve recently launched wearables integrations and improved AI-native clinical workflows - get in touch to see the latest updates.
Join us live: a physician's approach to social media
Building an audience as a doctor is its own skill, and most of us were never taught it.
On Wednesday, August 12 at 12:00 PM ET, Sunita Mohanty sits down with Dr. Hillary Lin, a Stanford-trained internist and co-founder of CareCore, and Dr. Mishal Reja, gastroenterologist and longevity physician at Extension Health, for a candid conversation on building a brand as a physician: why they started posting, what they have tried, and what has actually worked.
Register here for free.
In the news
The rules that let you prescribe controlled substances over telehealth expire on December 31. The DEA and HHS extended the pandemic-era flexibilities through the end of 2026 while they finalize a permanent special registration framework to replace them. If any part of your practice prescribes a controlled substance without an in-person visit first, the replacement rule decides how that works in January.
An AI early warning system cut hospital deaths by 18% in a 23,132-patient study. Researchers at RWJBarnabas Health and Rutgers published results in NEJM AI on July 29 from 11 hospitals running the Epic Deterioration Index, which rescores vital signs, labs, and nursing notes every 15 minutes and automatically pages the rapid response team when a patient hits the highest-risk tier. Deaths among high-risk patients fell from 23.1% to 18.6%. Note what did the work: no new sensor and no new data, only existing chart data scored continuously and routed to someone with the authority to act. That is the same lesson in an outpatient practice, where the labs and wearable trends are already arriving and the gap is whether anything reaches us in time to change the plan.
A shorter eating window protected thinking skills in older women. In a six-month randomized trial of 47 women aged 50 to 79 presented at NUTRITION 2026, the group eating within nine hours outperformed the twelve-hour group on planning and problem-solving, with similar weight loss in both arms. This is a conference abstract rather than a peer-reviewed paper, so hold it loosely with the patients already doing 16:8.
Upcoming Conferences & Events
Sept 22–23, MVMNT Longevity Medicine Summit · Coronado, CA · Evidence-graded longevity science, hands-on labs, and clinical frameworks you can implement the week after. Capped at 300 clinicians. Ultralight will be there!
Oct 8–10, A4M Women's Health Summit · San Antonio, TX · The best clinical education on hormone, metabolic, and midlife women's health you will see this year. The room to be in if you are growing the perimenopause and menopause side of your practice.
Oct 21–24, NAMS Annual Meeting · San Diego, CA · The single most practice-changing meeting of the year for midlife women's health. Your protocols will look different after this one.
Nov 5–8, Eudēmonia Summit · West Palm Beach, FL · One of the most talked-about longevity gatherings in the U.S. Experientials, hands-on demos, and the best place to try the emerging frameworks your patients will ask you about next year. Ovation and Ultralight will be there!
Nov 5-7, Private Physicians Alliance Annual Meeting · St. Petersburg, FL · The gathering for independent, cash-pay, and concierge physicians navigating practice independence. Practical and peer-driven. Ultralight will be there!
Nov 8-11, American College of Lifestyle Medicine Conference · Orlando, FL · Lifestyle medicine's main annual event — evidence-based approaches to behavior change, chronic disease, and healthspan. Growing overlap with the longevity medicine community.
Dec 11–13, A4M Longevity Fest · Las Vegas, NV · The biggest longevity event in the U.S. The room spans clinicians, industry, founders, and the people building next year's platforms, and the connections from this one tend to compound through the rest of your year. Ultralight will be there!
Know of an event we should add? Reply and tell us.
Until next Thursday
The vocabulary shift is the signal. When the largest pharma company in the world starts treating depression as a loss of plasticity rather than a shortage of serotonin, the model many of us have practiced for years stops being the alternative one. The compounds are years away. The conversations start this month.
Reply and tell us what your patients are asking about psychedelics, and how you answer them today. The best ideas in this newsletter come from clinicians doing the work.
Until next Thursday, keep building the practice you imagined when you started.
— Dr. G and Sunita